Genotype-Guided Diet and Exercise for Cardiometabolic Health

Recruiting in Palo Alto (17 mi)

Overseen by Pankaj Arora, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: University of Alabama at Birmingham

Must not be taking: Antidiabetics, Hypertension meds

Disqualifiers: Diabetes, Cardiovascular diseases, Pregnancy, others

No Placebo Group

Trial Summary

What is the purpose of this trial?

Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have \~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have \~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking more than two hypertension medications or have a history of diabetes or cardiovascular diseases.

What data supports the effectiveness of the treatment Genotype-Guided Diet and Exercise for Cardiometabolic Health?

Exercise is shown to improve blood sugar levels, increase insulin sensitivity, and enhance cardiovascular function, which are beneficial for people with diabetes. This suggests that the exercise component of the treatment could help improve cardiometabolic health. ^{1 2 3 4 5}

Is the Genotype-Guided Diet and Exercise for Cardiometabolic Health treatment generally safe for humans?

The research articles provided do not contain specific safety data for the Genotype-Guided Diet and Exercise treatment or its related components. ^{1 6 7 8 9}

How does the genotype-guided diet and exercise treatment differ from other treatments for cardiometabolic health?

This treatment is unique because it uses a person's genetic information to tailor diet and exercise plans, potentially improving cardiorespiratory fitness and reducing the risk of type 2 diabetes more effectively than standard approaches. It considers genetic variations that influence how individuals respond to lifestyle changes, making it a personalized approach to managing cardiometabolic health. ^{10 11 12 13 14}

Research Team

Pankaj Arora, MD

Principal Investigator

University of Alabama at Birmingham

Eligibility Criteria

This trial is for adults over 18 without a history of severe heart conditions like congestive heart failure, heart attack, or stroke. Participants should not be on insulin therapy but must be willing to follow the study protocol and consent to genetic material collection.

Inclusion Criteria

I do not take insulin.

You agree to follow the rules of the study.

I agree to provide samples for genetic testing.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

1 visit (in-person)

Dietary Intervention

Participants consume the study diet for 5 days

5 days

No visits required

Exercise Challenge

Participants undergo an exercise challenge test

1 day

1 visit (in-person)

Glucose Challenge

Participants consume 75 gm of oral glucose followed by blood collection every 8 hours

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the challenges

2 weeks

Treatment Details

Interventions

• Exercise capacity VO2 max determination (Behavioural Intervention)
• Exercise Challenge (Behavioural Intervention)
• Glucose Challenge (Behavioural Intervention)
• Study diet (Other)

Trial Overview The GENESIS study is looking at how diet and exercise affect hormones produced by the heart called Natriuretic Peptides (NP), which are linked to cardiometabolic health. It will involve an exercise challenge, glucose challenge, and VO2 max determination.

Participant Groups

Group I: Experimental: Low NP Genotype Group Experimental Treatment 4 Interventions

150 healthy adult participants with low NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.

Group II: Active Comparator: High NP Genotype Group Experimental Treatment 4 Interventions

50 healthy adult participants with high NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University of Alabama at Birmingham Birmingham, AL

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials

1677

Recruited

2,458,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials

3987

Recruited

47,860,000+

Zachariah McIver

National Heart, Lung, and Blood Institute (NHLBI)

Chief Medical Officer

D.O. from Ohio University College of Osteopathic Medicine, Ph.D. in Molecular Medicine and Translational Sciences from Wake Forest University School of Medicine

James F. Holmes

National Heart, Lung, and Blood Institute (NHLBI)

Co-Principal Investigator, National Heart, Lung, and Blood Institute K12 Program since 2011

MD from the University of Alabama, School of Medicine

Findings from Research

In a study of 23 participants with type 2 diabetes, the GLP-1 agonist exenatide improved diastolic cardiac function and reduced arterial stiffness, indicating potential cardiovascular benefits.

However, exenatide did not enhance overall exercise capacity, suggesting that combining it with aerobic exercise training may be necessary to fully realize its benefits for patients with type 2 diabetes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes. Scalzo, RL., Moreau, KL., Ozemek, C., et al.[2022]

In a study of 105 participants with impaired glucose tolerance or type 2 diabetes, 90% showed improved insulin sensitivity after 12 to 16 weeks of aerobic exercise training, indicating that exercise can significantly enhance metabolic health.

The variability in glycemic control improvements was primarily linked to changes in pancreatic β-cell function, particularly in insulin secretion, rather than insulin sensitivity, suggesting that individual responses to exercise may depend on baseline β-cell function.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pancreatic β-cell function is a stronger predictor of changes in glycemic control after an aerobic exercise intervention than insulin sensitivity. Solomon, TP., Malin, SK., Karstoft, K., et al.[2022]

Individuals with type 1 diabetes (T1D) showed stable blood glucose (BG) levels during cardiopulmonary exercise testing (CPET), indicating that exercise does not significantly alter BG in this population.

Higher preexercise BG levels were associated with increased heart rate and lactate production during exercise, while HbA1c levels were linked to lower peak performance outcomes, suggesting that long-term glucose control impacts exercise capacity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Blood Glucose Responses during Cardiopulmonary Incremental Exercise Testing in Type 1 Diabetes: A Pooled Analysis. McCarthy, O., Pitt, J., Wellman, B., et al.[2023]

In a study involving 38 adults with type 2 diabetes, the DPP4-inhibitor sitagliptin improved cardiac diastolic function but did not lead to any changes in cardiorespiratory fitness (CRF) after 3 months of treatment.

Both sitagliptin and glimepiride effectively reduced fasting glucose levels compared to placebo, but targeting physiological contributors to CRF with sitagliptin alone was insufficient to enhance CRF in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes. Scalzo, RL., Rafferty, D., Schauer, I., et al.[2022]

In a study of 12 healthy volunteers, higher cardiorespiratory fitness (CRF), measured by peak oxygen uptake (VO2peak), was strongly associated with better insulin sensitivity, as indicated by positive correlations with glucose infusion rates at rest and during exercise.

The findings suggest that maintaining good CRF is crucial for normal insulin action and metabolic health, as higher VO2peak was linked to lower insulin secretion, indicating a more efficient insulin response.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cardiorespiratory fitness predicts insulin action and secretion in healthy individuals. Larsen, FJ., Anderson, M., Ekblom, B., et al.[2018]

In a study of 38 pairs of young monozygotic twins, those with higher cardiorespiratory fitness (VO2max) had significantly lower fasting glucose levels, suggesting a link between fitness and better glucose metabolism.

Despite the differences in fitness levels, there were no significant variations in fasting insulin levels between the more and less active twins, indicating that cardiorespiratory fitness may specifically influence glucose regulation rather than insulin levels.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Glucose metabolism in discordant monozygotic twins for cardiorespiratory fitness. Queiroga, MR., Barbieri, RA., Ferreira, SA., et al.[2019]

References

1. United States pubmed.ncbi.nlm.nih.gov

Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

Pancreatic β-cell function is a stronger predictor of changes in glycemic control after an aerobic exercise intervention than insulin sensitivity. [2022]

3. England pubmed.ncbi.nlm.nih.gov

Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes. [2016]

4. England pubmed.ncbi.nlm.nih.gov

Integrating metabolic expenditure information from wearable fitness sensors into an AI-augmented automated insulin delivery system: a randomised clinical trial. [2023]

5. England pubmed.ncbi.nlm.nih.gov

Exercise and diabetes. [2011]

6. United States pubmed.ncbi.nlm.nih.gov

Blood Glucose Responses during Cardiopulmonary Incremental Exercise Testing in Type 1 Diabetes: A Pooled Analysis. [2023]

7. United States pubmed.ncbi.nlm.nih.gov

Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes. [2022]

8. United States pubmed.ncbi.nlm.nih.gov

Cardiorespiratory fitness predicts insulin action and secretion in healthy individuals. [2018]

9. Germany pubmed.ncbi.nlm.nih.gov

Does metformin modify the effect on glycaemic control of aerobic exercise, resistance exercise or both? [2022]

10. United States pubmed.ncbi.nlm.nih.gov

Genetic modifiers of cardiorespiratory fitness response to lifestyle intervention. [2021]

11. United States pubmed.ncbi.nlm.nih.gov

Advances in exercise, fitness, and performance genomics in 2014. [2018]

12. Brazil pubmed.ncbi.nlm.nih.gov

Glucose metabolism in discordant monozygotic twins for cardiorespiratory fitness. [2019]

13. United States pubmed.ncbi.nlm.nih.gov

Advances in exercise, fitness, and performance genomics in 2011. [2021]

14. United States pubmed.ncbi.nlm.nih.gov

Influence of the interleukin-6 -174 G/C gene polymorphism on exercise training-induced changes in glucose tolerance indexes. [2013]